EnteroMedics Inc.™ Announces Pivotal Clinical Study of its VBLOC™ Therapy for Obesity

ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics, Inc. (NASDAQ:ETRM), a developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced its EMPOWER pivotal clinical study. The FDA has recently granted approval for the pivotal clinical study of the company’s investigational VBLOC Therapy using the Maestro™ System, its initial product for the treatment of obesity. The EMPOWER Study will evaluate the safety and effectiveness of the Company’s proprietary VBLOC™ vagal blocking therapy for the treatment of obesity at 15 clinical sites in the U.S. and Australia.